Prashant Poddar co-wrote this blog post with Jon Roffman.
As the SARS-CoV-2 pandemic rages on, questions remain about how the virus is transmitted between people, how quickly it spreads and how contagious it is. But one thing is certain: The elderly and immunosuppressed patient populations, including those with cancer, are among the most at risk.
These patients need oncology manufacturers, healthcare providers and other stakeholders to ensure that they have continued access to care while minimizing exposure to the virus. Together, we can play a critical role in helping to improve and extend the lives of oncology patients. This should be our central focus today, knowing that it likely will change the way that we approach tomorrow and beyond.
Arun Jain co-wrote this blog post with Arup Das.
Imagine a world where oncology analytics transform the way that a pharma manufacturer engages with its customer: Sales reps have real-time insight into where patients are being diagnosed. Accurate predictions help them anticipate when to follow up with a customer with a relevant message about their soon-to-relapse patient. Customers give them unencumbered access because they trust that the manufacturer will engage with them through their preferred channels at the right cadence. Does this sound too good to be true? Some oncology companies are already exploring these possibilities today, but according to ZS’s recent benchmarking study of oncology analytics organizations, many are not there yet in their analytics maturity and are missing out on critical opportunities to engage their customers when it matters most.